Table of Contents

Type 2 diabetes is the most common form of diabetes, mainly affecting adults, and occurs when the body either develops insulin resistance or doesn’t produce sufficient amounts. Over the past 30 years, the incidence of type 2 diabetes has surged dramatically across countries, regardless of their economic status.

Mounjaro, a new treatment gaining attention, has shown potential for effective diabetes management and improving overall quality of life. In this article, we will explore how this popular medication works, its benefits, and its effectiveness, backed by recent research and clinical trials.

Key Takeaways

  • Mounjaro targets both GIP and GLP-1 receptors, offering a unique dual approach to blood sugar management.
  • Mounjaro has demonstrated greater effectiveness in lowering HbA1c levels and supporting weight loss compared to other diabetes medications like semaglutide and insulin glargine in the SURPASS trials.
  • Mounjaro may offer additional therapeutic benefits, including improved liver health, renal protection, and potential neuroprotective effects against neurodegenerative diseases like Alzheimer’s.
  • While Mounjaro generally causes fewer gastrointestinal issues than other GLP-1 receptor agonists, common side effects include nausea and vomiting.
  • Mounjaro is contraindicated in patients with certain thyroid conditions due to a potential risk of thyroid tumors.

What is Mounjaro?

What is Mounjaro?

Mounjaro, also known by its generic name tirzepatide, is a once-weekly injectable medication developed by Eli Lilly for treating type 2 diabetes. It was approved by the US Food and Drug Administration (FDA) in May 2022 based on extensive clinical trials that demonstrated its effectiveness.

It’s the first and only diabetic drug in a new class known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. By targeting these receptors, Mounjaro offers a unique approach to managing blood sugar levels.

How Does Mounjaro Work for Diabetes?

Mounjaro mimics the effects of two naturally occurring hormones—GIP and GLP-1—that are involved in regulating blood sugar levels.

1. GLP-1 Receptor Activation

The GLP-1 receptor stimulates insulin release in a glucose-dependent manner, meaning insulin is secreted only when blood sugar levels are elevated. It also inhibits glucagon release, preventing the liver from producing more glucose.

A study showed that prolonged GLP-1 receptor stimulation led to metabolic changes in beta-cells, including increased glucose uptake, glycolysis (the breakdown of glucose for energy), and insulin secretion. The cells also produced more ATP, indicating heightened metabolism and better glucose handling.

This improved metabolic activity suggests that beta-cells are better equipped to support insulin production and maintain normal blood sugar levels.

Good to know: Beta-cells are cells found in the pancreas that produce and release insulin, the hormone responsible for lowering blood sugar. In individuals with diabetes, beta-cell function is often impaired.

2. GIP Receptor Activation

Unlike GLP-1, GIP primarily impacts insulin sensitivity in adipose (fat) tissue. Research shows that GIPR activation can promote the growth of white adipose tissue (WAT), which is the body’s main fat storage tissue.

After eating, WAT absorbs dietary fats by breaking them down with an enzyme that is activated by insulin. During fasting, WAT releases these stored fats as free fatty acids, providing energy for the body. Its ability to switch between storing fats after meals and releasing them during fasting is essential for maintaining overall metabolic health.

Along with improving fat management, GIP may offer additional metabolic benefits when it acts in the central nervous system. Specifically, it can help reduce energy intake, meaning it may suppress appetite.

When GIP is combined with GLP-1, the effects are even stronger. Rodent studies showed that using both GIP and GLP-1 together resulted in greater appetite suppression and more significant weight loss than using either hormone alone.

Essentially, combining GIP and GLP-1 could provide a more effective way to regulate blood sugar, reduce appetite, and promote weight loss, potentially helping people with type 2 diabetes.

How Effective is Mounjaro for Diabetes Management?

The SURPASS trials evaluated the safety and efficacy of Mounjaro in comparison to other diabetes medications such as insulin glargine, semaglutide, and placebo.

The results were compelling, with Mounjaro consistently demonstrating superior efficacy in reducing HbA1c (a marker of long-term blood sugar management) and promoting weight loss.

    • SURPASS-2 Trial:

This trial compared tirzepatide to semaglutide, a popular GLP-1 receptor agonist. Patients receiving tirzepatide achieved significantly greater reductions in HbA1c levels (up to 2.4%) compared to those on semaglutide (1.9%).

Furthermore, participants on tirzepatide experienced up to 25 lbs of weight loss compared to 13 lbs with semaglutide.

    • SURPASS-4 Trial:

In this trial, tirzepatide was compared to insulin glargine in individuals with type 2 diabetes who were at high risk for cardiovascular events.

Mounjaro not only demonstrated superior glycemic control (HbA1c reduction of 2.5% compared to 1.4% with insulin glargine) but also led to an average weight loss of up to 23 lbs compared to weight gain in the insulin group.

What Are the Potential Benefits of Mounjaro Beyond Diabetes?

Tirzepatide could have broader therapeutic applications, including:

1. Metabolic dysfunction–associated steatohepatitis (MASH)

MASH is a liver disease linked to fat accumulation and metabolic dysfunction, which can lead to serious complications like fibrosis (scarring of the liver) and cirrhosis (severe liver damage).

In a 2024 study conducted in the US, 13.6% of individuals with type 2 diabetes were found to have at-risk MASH, with the prevalence even higher among those who also had obesity.

A 52-week phase II trial demonstrated that tirzepatide significantly improved liver health in patients with MASH and moderate to severe fibrosis, with up to 62% of participants achieving resolution of MASH without worsening fibrosis. However, larger and longer trials are necessary to confirm these findings and ensure the safety of tirzepatide for MASH treatment.

2. Renal Protection

A post-hoc analysis of SURPASS-4 highlighted that tirzepatide reduced the amount of protein in the urine (a sign of kidney damage) and slowed the decline in kidney function. Compared to insulin, it nearly cut the risk of severe kidney issues like kidney failure in half.

This is particularly important because diabetes is a leading cause of kidney damage. According to the National Kidney Foundation, 10-40% of people with type 2 diabetes is expected develop kidney failure.

3. Neurodegenerative Disease

Increasing evidence suggests that Alzheimer’s disease (AD) may be a form of brain-specific diabetes, often referred to as type 3 diabetes. Insulin resistance is a key factor in both AD and type 2 diabetes, indicating that treatments for type 2 diabetes may also help with neuroinflammation and neurodegenerative conditions like AD.

Preliminary studies show that incretin-based drugs could provide neuroprotective benefits, potentially slowing the progression of diseases like Alzheimer’s and Parkinson’s.

Notably, research on a GIP/GLP-1 dual agonist found that it crosses the blood-brain barrier faster than semaglutide, potentially offering better outcomes.

What are the Side Effects of Mounjaro?

The most frequently reported side effects of Mounjaro in clinical trials include:

    • Gastrointestinal Issues: This includes nausea, diarrhea, and constipation, especially during the initial weeks of treatment. However, a study mentioned that tirzepatide tends to cause fewer gastrointestinal issues than other GLP-1RAs. This is likely due to its dual agonistic action, which favors the GIP receptor over the GLP-1 receptor.

High doses of GLP-1R agonists are known to worsen gastrointestinal discomfort. Interestingly, GIP itself doesn’t cause such side effects, even at high concentrations.

    • Injection Site Reactions: Certain patients may develop redness, itching, or discomfort at the injection site.
    • Hypoglycemia: While all glucose-lowering drugs carry a risk of hypoglycemia (low blood sugar), tirzepatide’s risk of hypoglycemia is lower when used without other insulin-stimulating drugs.

Despite having fewer gastrointestinal issues, tirzepatide’s side effects remain dose-dependent. They increase with higher doses but often occur during the transition to a new dose.

How is Mounjaro Administered?

Mounjaro is administered as a once-weekly injection, typically in the abdomen, thigh, or upper arm. The dose is titrated based on the patient’s response and tolerance, starting at 5 mg and increasing to 10 mg or 15 mg if needed.

It is important for patients to follow their healthcare provider’s instructions regarding dosage and administration. Proper injection technique is crucial to reduce the risk of adverse reactions and ensure the drug is delivered effectively.

Related article: Looking for Mounjaro injection instructions? Our detailed article on how to inject Mounjaro provides step-by-step guidance to make the process easy!

How Much Does Mounjaro Cost for Diabetes Treatment?

The cost of Mounjaro can vary depending on factors such as insurance coverage, location, and pharmacy. Without insurance, the out-of-pocket cost for Mounjaro typically ranges between $900 to $1,200 for a monthly supply, which contains four injections.

For those with insurance, coverage for Mounjaro will depend on the specific plan and whether the medication is included in the formulary. Co-pays for insured patients can range from $25 to $150 per month, depending on the policy.

Some manufacturers also offer savings cards or discount programs that can significantly reduce the cost for eligible patients. These programs may bring the monthly cost down to as little as $25.

Order Mounjaro from Pharma Giant Today!

At Pharma Giant, you can save up to 90% on prescription medications such as Mounjaro. Plus, you can enjoy additional discounts and offers when ordering larger quantities.

To save more, use the coupon code PGSAVE10 for a 10% discount on your first order. Pharma Giant promises expedited delivery, with medications typically arriving within 3-5 business days.

Buy Mounjaro KwikPen from Canada

from $499.97/pen

Wrap Up

Mounjaro marks a major breakthrough in the treatment of type 2 diabetes. Clinical trials have shown its effectiveness in lowering HbA1c levels, promoting substantial weight loss, and potentially offering cardiovascular benefits.

For those struggling to manage type 2 diabetes, Mounjaro offers hope for overall health outcomes. As with any medication, it is important to work closely with a professional when using Mounjaro for diabetes.

Frequently Asked Questions

Mounjaro should be refrigerated between 36°F and 46°F (2°C to 8°C) and kept away from direct light. If necessary, it can be stored at room temperature (up to 86°F) for a maximum of 21 days.

Mounjaro is not currently approved for the treatment of prediabetes, though some doctors may prescribe it off-label. Consult your healthcare provider for personalized advice.

Mounjaro is not officially approved for weight loss. However, a medication with the same active ingredient, called Zepbound, has been approved for weight loss.

Side effects of Mounjaro may begin within hours or days after injection, depending on the individual.

Mounjaro comes in a box containing four single-dose pens, intended for weekly injections.

Doctors typically prescribe Mounjaro based on factors like your HbA1c levels (usually if it’s elevated above 7%) and how well your blood sugar is controlled with other treatments. They may also consider your weight, cardiovascular risk, and whether you’ve had success with other diabetes medications before deciding on the dosage.

Coverage for Mounjaro under Tricare, Medicaid, or Medicare varies, and it is best to check directly with your insurance provider for specific coverage details.

Alternatives to Mounjaro for weight loss include Wegovy, Saxenda and Zepbound, which are also GLP-1 receptor agonists.

Mounjaro is only available as a subcutaneous injection and not in oral form.

Both Ozempic and Mounjaro are effective for diabetes management, but Mounjaro may offer better glucose control due to its dual-action mechanism. However, the best option depends on individual patient needs and doctor recommendations.

Related Articles

References

Eli Lilly. (NA). Official Website. https://www.lilly.com/

PRNewswire. (May, 2022). FDA approves Lilly’s MounjaroTM (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Eliu and Company. Retrieved from https://investor.lilly.com/

Carlessi, R., Chen, Y., Rowlands, J., Cruzat, V. F., Keane, K. N., Egan, L., Mamotte, C., Stokes, R., Gunton, J. E., De Bittencourt, P. I. H., & Newsholme, P. (2017). GLP-1 receptor signalling promotes ?-cell glucose metabolism via mTOR-dependent HIF-1? activation. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-02838-2

Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., Lockie, S. H., Smiley, D. L., Gelfanov, V., Yang, B., Hofmann, S., Bruemmer, D., Drucker, D. J., Pfluger, P. T., Perez-Tilve, D., . . . Tschöp, M. H. (2013). Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine, 5(209). https://doi.org/10.1126/scitranslmed.3007218

Taktaz, F., Fontanella, R. A., Scisciola, L., Pesapane, A., Basilicata, M. G., Ghosh, P., Franzese, M., Tortorella, G., Puocci, A., Vietri, M. T., Capuano, A., Paolisso, G., & Barbieri, M. (2024). Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide. Cardiovascular Diabetology, 23(1). https://doi.org/10.1186/s12933-024-02319-7

Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020). How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology and Metabolism, 31(6), 410–421. https://doi.org/10.1016/j.tem.2020.02.006

Frías, J. P., Davies, M. J., Rosenstock, J., Manghi, F. C. P., Landó, L. F., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021b). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/nejmoa2107519

Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., Wiese, R. J., Ahmann, A. J., Arora, S., Ball, E. M., Calderon, R. B., Butuk, D. J., Chaychi, L., Chen, M. C., Curtis, B. M., . . . Kotsa, K. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398(10313), 1811–1824. https://doi.org/10.1016/s0140-6736(21)02188-7

Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., Van Der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D’Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17). https://doi.org/10.1172/jci.insight.140532

Ma, Z., Jin, K., Yue, M., Chen, X., & Chen, J. (2023). Research progress on the GIP/GLP-1 receptor coagonist tirzepatide, a rising star in type 2 diabetes. Journal of Diabetes Research, 2023, 1–8. https://doi.org/10.1155/2023/5891532

Mittal, N., Siddiqi, H., Madamba, E., Richards, L., Bettencourt, R., Ajmera, V., & Loomba, R. (2024). A prospective study on the prevalence of at?risk MASH in patients with type 2 diabetes mellitus in the United States. Alimentary Pharmacology & Therapeutics, 59(12), 1571–1578. https://doi.org/10.1111/apt.17997

Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., & Sanyal, A. J. (2024). Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2401943

National Kidney Foundation. (NA). Diabetes – A Major Risk Factor for Kidney Disease. Retrieved from https://www.kidney.org/kidney-topics/diabetes-major-risk-factor-kidney-disease

Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022). Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. The Lancet Diabetes & Endocrinology, 10(11), 774–785. https://doi.org/10.1016/s2213-8587(22)00243-1

Zhang, L., Li, C., Zhang, Z., Zhang, Z., Jin, Q., Li, L., & Hölscher, C. (2022). DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce ?-Synuclein Levels in the 6-OHDA Parkinson’s Disease Rat Model. Parkinson S Disease, 2022, 1–11. https://doi.org/10.1155/2022/1428817